August 27, 2024 – Vaderis Therapeutics

Skip to content

Home
Medical Need
Our Science
Our Team
News

Home
Medical Need
Our Science
Our Team
News

Home
Medical Need
Our Science
Our Team
News
Contact Us

Home
Medical Need
Our Science
Our Team
News
Contact Us

Vaderis News |

12/02/2025

Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results

Vaderis News |

11/17/2024

Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia

Vaderis News |

11/05/2024

Vaderis Announces Acceptance of Abstract on VAD044 Proof-of-Concept Clinical Trial

Vaderis News |

08/27/2024

Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT

Vaderis News |

08/22/2022

Vaderis Therapeutics AG announces Clinical Proof-of-Concept Trial in HHT

Home
Medical Need
Our Science
Our Team
News

Home
Medical Need
Our Science
Our Team
News

© 2026 Vaderis Therapeutics. Vaderis™ is a trademark of Vaderis Therapeutics AG in the United States, European Union, and Switzerland.

Social

Privacy Statement

Contact

Switzerland
Building WSJ-350
Lichtstrasse 35
CH-4056 Basel
+1 844 823 3747

USA
250 Parkway Drive
Suite 360
Lincolnshire, IL 60069
+1 844 823 3747

Home
Medical Need
Our Science
Our Team
News

Home
Medical Need
Our Science
Our Team
News

Social

Privacy Statement

Contact

Terms of Use

USA
250 Parkway Drive
Suite 360
Lincolnshire, IL 60069
+1 844 823 3747

Switzerland
Building WSJ-350
Lichtstrasse 35
CH-4056 Basel
+1 844 823 3747

© 2026 Vaderis Therapeutics.
Vaderis™ is a trademark of Vaderis Therapeutics AG in the United States, European Union, and Switzerland.